Concurrent use of Sr-89 chloride with zoledronic acid is safe and effective for breast cancer patients with painful bone metastases

Yamada,Kimito; Yoshimura,Mana; Kaise,Hiroshi; Ogata,Akihiko; Ueda,Naoko; Tokuuye,Koichi; Kohno,Norio

doi:10.3892/etm.2011.405

February 2012 Volume 3 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

February 2012 Volume 3 Issue 2

Full Size Image

Article

Concurrent use of Sr-89 chloride with zoledronic acid is safe and effective for breast cancer patients with painful bone metastases

Authors:
- Kimito Yamada
- Mana Yoshimura
- Hiroshi Kaise
- Akihiko Ogata
- Naoko Ueda
- Koichi Tokuuye
- Norio Kohno
View Affiliations / Copyright

Affiliations: Department of Breast Oncology, Tokyo Medical University Hospital, Tokyo 160-0023, Japan, Department of Radiology, Tokyo Medical University, Tokyo, Japan
Pages: 226-230
|
Published online on: December 2, 2011

https://doi.org/10.3892/etm.2011.405
Expand metrics +

Abstract

Our aim in this study was to examine the safety and efficacy of the concurrent use of the radiopharmaceutical strontium-89 (Sr-89) chloride with zoledronic acid in standard anticancer therapy for breast cancer patients with painful multifocal bone metastases. The study comprised 16 breast cancer patients with painful multifocal bone metastases detected by bone scintigraphy, computed tomography or magnetic resonance imaging. All patients were treated with Sr-89 and zoledronic acid concurrently between March 2007 and February 2011 as part of a standard therapeutic regimen comprising chemotherapy, endocrine therapy, molecular targeting therapy and targeted radiotherapy. Sr-89 was administered intravenously at 2 MBq/kg to a maximum of 141 MBq per person. Safety was evaluated according to myelotoxicity as measured by the Common Terminology Criteria for Adverse Events (v3.0). To assess treatment efficacy, we monitored changes in analgesic drug dosages. Furthermore, bremsstrahlung imaging after the administration of Sr-89 was utilized to examine the relationship between the accumulation of Sr-89 in metastatic sites and treatment efficacy. Based on the results, a total of 14 out of 16 patients (88%) reported bone pain relief, indicating a high efficacy of Sr-89 combined with zoledronic acid. In responsive cases, a strong uptake of Sr-89 was observed on bremsstrahlung imaging at the same sites indicated by 99mTc bone scintigraphy. Moreover, severe myelosuppression (> grade 3) was not observed, and adverse events were tolerable. In conclusion, the use of Sr-89 with zoledronic acid in breast cancer patients with painful bone metastases was safe and effective when administered concurrently with other standard therapies. In the future, the treatment with Sr-89 at the early stage should be considered, and a large-scale clinical study should be conducted.

View Figures

View References

1.	D TongL GillickFR HendricksonThe palliation of symptomatic osseous metastases: final results of the study by the Radiation Therapy Oncology GroupCancer50893899198210.1002/1097-0142(19820901)50:5%3C893::AID-CNCR2820500515%3E3.0.CO;2-Y6178497
2.	RE ColemanRD RubensThe clinical course of bone metastases from breast cancerBr J Cancer556166198710.1038/bjc.1987.133814476
3.	N KohnoTreatment of breast cancer with bone metastasis: bisphosphonate treatment – current and futureInt J Oncol1318232008
4.	M GnantB MlineritschW SchippingerEndocrine therapy plus zoledronic acid in premenopausal breast cancerN Engl J Med360679691200910.1056/NEJMoa080628519213681
5.	M GnantB MlineritschH StoegerAdjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trialLancet Oncol12631641201110.1016/S1470-2045(11)70122-X21641868
6.	Society of Nuclear Medicine Procedure Guideline for Palliative Treatment of Painful Bone Metastases ver.3.0 (http://interactive.snm.org/docs/pg_ch25_0403.pdf).
7.	EB SilbersteinAT Taylor JrEANMEANM Procedure Guidelines for Treatment of Refractory Metastatic Bone PainEur J Nucl Med30BP7BP11200310.1007/s00259-002-1057-112723557
8.	G StortoM KlainG PaoneCombined therapy of Sr-89 and zoledronic acid in patients with painful bone metastasesBone393541200610.1016/j.bone.2005.12.00416434248
9.	M NishioM SanoY TamakiA multicenter study to determine the efficacy and safety of strontium (89Sr) chloride for palliation of painful bony metastases in cancer patientsNippon Acta Radiologica65399410200516334394
10.	IG FinlayMD MasonM ShelleyRadioisotopes for the palliation of metastatic bone cancer: a systematic reviewLancet Oncol6392400200510.1016/S1470-2045(05)70206-015925817
11.	M UchiyamaH NaritaM MakinoStrontium-89 therapy and imaging with bremsstrahlung in bone metastasesClin Nucl Med22605609199710.1097/00003072-199709000-000059298293
12.	N BaziotisE YakoumakisA ZissimopoulosStrontium-89 chloride in the treatment of bone metastases from breast cancerOncology55377381199810.1159/0000118819732212
13.	W AkerleyJ ButeraT WehbeA multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving boneCancer9416541660200210.1002/cncr.10437
14.	SM TuRE MillikanB MengistuBone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized phase II trialLancet357336341200110.1016/S0140-6736(00)03639-411210994
15.	R SciutoA FestaS ReaEffects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trialJ Nucl Med437986200211801708
16.	SM TuJ KimLC PagliaroTherapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapyJ Clin Oncol2379047910200510.1200/JCO.2005.01.231016258090
17.	E PorfiriInitial feasibility and safety results from a phase II/III clinical trial to evaluate docetaxel (D) therapy in combination with zoledronic acid (ZA) ± strontium-89 (Sr89) in hormone-refractory prostate cancer patientsJ Clin Oncol28S7abs 46772010
18.	AJ McEwanUse of radionuclides for the palliation of bone metastasesSemin Radiat Oncol10103114200010.1016/S1053-4296(00)80047-810727599
19.	AN SerafiniTherapy of metastatic bone painJ Nucl Med42895906200111390554
20.	AH LaingDM AckeryRJ BaylyStrontium-89 chloride for pain palliation in prostatic skeletal malignancyBr J Radiol64816822199110.1259/0007-1285-64-765-8161717094
21.	F Kraeber-BodéréL CampionC RousseauTreatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvementEur J Nucl Med2714871493200011083537
22.	PM WindsorPredictors of response to strontium-89 (Metastron) in skeletal metastases from prostate cancer: report of a single centre’s 10-year experienceClin Oncol (R Coll Radiol)13219227200111527299
23.	EB SilbersteinC WilliamsStrontium-89 therapy for the pain of osseous metastasesJ Nucl Med2634534819853920361
24.	EB SilbersteinTeletherapy and radiopharmaceutical therapy of painful bone metastasesSemin Nucl Med35152158200510.1053/j.semnuclmed.2004.11.00615765378
25.	MG LamJM de KlerkPP van RijkBA ZonnenbergBone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastasesAnticancer Agents Med Chem.7381397200710.2174/18715200778105859617630915

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Concurrent use of Sr-89 chloride with zoledronic acid is safe and effective for breast cancer patients with painful bone metastases

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles